AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2022 Results Conference Call April 7, 2022 8:00 AM ET
Company Participants
Jim Clemmer - President and Chief Executive Officer
Steve Trowbridge - Executive Vice President and Chief Financial Officer
Conference Call Participants
Jayson Bedford - Raymond James
Bill Plovanic - Canaccord Genuity
Steven Lichtman - Oppenheimer & Company
Matthew Mishan - KeyBanc Capital Markets
Operator
Good morning, and welcome to the AngioDynamics' Fiscal Year 2022 Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference call is being recorded.
The news release detailing the fiscal 2022 third quarter results crossed the wire earlier this morning and is available on the Company's website. This conference call is also being broadcast live over the Internet at the Investors section of the Company's website at www.angiodynamics.com. And the webcast replay of this call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I'd like to caution listeners that during the course of this conference call, the Company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and gross margins for the fiscal year 2022, as well as trends that may continue. Management encourages you to review the Company's past and future filings with the SEC, including, without limitation, the Company's Forms 10-Q and 10-K, which identify specific factors that may cause actual results to differ materially from those described in the forward-looking statements.
The Company will also discuss certain non-GAAP financial measures during this call. Management uses these measures to establish operational goals and review operational performance and believes that these measures may assist investors in analyzing the underlying trends in the Company's business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP.
A slide package offering insight into the Company's financial results is also available on the Investors section of the Company's website under Events and Presentations. This presentation should be read in conjunction with the press release discussing the Company's operational results and financial performances during this morning's conference call.
I'd now like to turn the call over to Jim Clemmer, AngioDynamics' President and Chief Executive Officer. Mr. Clemmer?
Jim Clemmer